UNLABELLED: Glycerol phenylbutyrate (glyceryl tri (4-phenylbutyrate)) (GPB) is being studied as an alternative to sodium phenylbutyrate (NaPBA) for the treatment of urea cycle disorders (UCDs). This phase 2 study explored the hypothesis that GPB offers similar safety and ammonia control as NaPBA, which is currently approved as adjunctive therapy in the chronic management of UCDs, and examined correlates of 24-h blood ammonia. METHODS: An open-label, fixed sequence switch-over study was conducted in adult UCD patients taking maintenance NaPBA. Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA). RESULTS: Ten subjects completed the study. Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB. Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis. Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar. Urinary PAGN excretion accounted for approximately 54% of PBA administered for both NaPBA and GPB; other metabolites accounted for <1%. Intact GPB was generally undetectable in blood and urine. Blood ammonia correlated strongly and inversely with urinary PAGN (r=-0.82; p<0.0001) but weakly or not at all with blood metabolite levels. CONCLUSIONS: Safety and ammonia control with GPB appear at least equal to NaPBA. Urinary PAGN, which is stoichiometrically related to nitrogen scavenging, may be a useful biomarker for both dose selection and adjustment for optimal control of venous ammonia. Copyright 2010 Elsevier Inc. All rights reserved.
UNLABELLED: Glycerol phenylbutyrate (glyceryl tri (4-phenylbutyrate)) (GPB) is being studied as an alternative to sodium phenylbutyrate (NaPBA) for the treatment of urea cycle disorders (UCDs). This phase 2 study explored the hypothesis that GPB offers similar safety and ammonia control as NaPBA, which is currently approved as adjunctive therapy in the chronic management of UCDs, and examined correlates of 24-h blood ammonia. METHODS: An open-label, fixed sequence switch-over study was conducted in adult UCD patients taking maintenance NaPBA. Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA). RESULTS: Ten subjects completed the study. Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB. Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis. Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar. Urinary PAGN excretion accounted for approximately 54% of PBA administered for both NaPBA and GPB; other metabolites accounted for <1%. Intact GPB was generally undetectable in blood and urine. Blood ammonia correlated strongly and inversely with urinary PAGN (r=-0.82; p<0.0001) but weakly or not at all with blood metabolite levels. CONCLUSIONS: Safety and ammonia control with GPB appear at least equal to NaPBA. Urinary PAGN, which is stoichiometrically related to nitrogen scavenging, may be a useful biomarker for both dose selection and adjustment for optimal control of venous ammonia. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw Journal: Mol Genet Metab Date: 2008-06-17 Impact factor: 4.797
Authors: Fernando Scaglia; Nicola Brunetti-Pierri; Soledad Kleppe; Juan Marini; Susan Carter; Peter Garlick; Farook Jahoor; William O'Brien; Brendan Lee Journal: J Nutr Date: 2004-10 Impact factor: 4.798
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Takhar Kasumov; Laura L Brunengraber; Blandine Comte; Michelle A Puchowicz; Kathryn Jobbins; Katherine Thomas; France David; Renee Kinman; Suzanne Wehrli; William Dahms; Douglas Kerr; Itzhak Nissim; Henri Brunengraber Journal: Drug Metab Dispos Date: 2004-01 Impact factor: 3.922
Authors: Uta Lichter-Konecki; G A Diaz; J L Merritt; A Feigenbaum; C Jomphe; J F Marier; M Beliveau; J Mauney; K Dickinson; A Martinez; M Mokhtarani; B Scharschmidt; W Rhead Journal: Mol Genet Metab Date: 2011-05-05 Impact factor: 4.797
Authors: Gulab S Zode; Kevin E Bugge; Kabhilan Mohan; Sinisa D Grozdanic; Joseph C Peters; Demelza R Koehn; Michael G Anderson; Randy H Kardon; Edwin M Stone; Val C Sheffield Journal: Invest Ophthalmol Vis Sci Date: 2012-03-21 Impact factor: 4.799
Authors: Wendy Smith; George A Diaz; Uta Lichter-Konecki; Susan A Berry; Cary O Harding; Shawn E McCandless; Cindy LeMons; Joe Mauney; Klara Dickinson; Dion F Coakley; Tristen Moors; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee Journal: J Pediatr Date: 2013-01-13 Impact factor: 4.406
Authors: George A Diaz; Lauren S Krivitzky; Masoud Mokhtarani; William Rhead; James Bartley; Annette Feigenbaum; Nicola Longo; William Berquist; Susan A Berry; Renata Gallagher; Uta Lichter-Konecki; Dennis Bartholomew; Cary O Harding; Stephen Cederbaum; Shawn E McCandless; Wendy Smith; Gerald Vockley; Stephen A Bart; Mark S Korson; David Kronn; Roberto Zori; J Lawrence Merritt; Sandesh C S Nagamani; Joseph Mauney; Cynthia Lemons; Klara Dickinson; Tristen L Moors; Dion F Coakley; Bruce F Scharschmidt; Brendan Lee Journal: Hepatology Date: 2013-01-03 Impact factor: 17.425
Authors: M Mokhtarani; G A Diaz; W Rhead; S A Berry; U Lichter-Konecki; A Feigenbaum; A Schulze; N Longo; J Bartley; W Berquist; R Gallagher; W Smith; S E McCandless; C Harding; D C Rockey; J M Vierling; P Mantry; M Ghabril; R S Brown; K Dickinson; T Moors; C Norris; D Coakley; D A Milikien; S C Nagamani; C Lemons; B Lee; B F Scharschmidt Journal: Mol Genet Metab Date: 2013-10-08 Impact factor: 4.797
Authors: M Mokhtarani; G A Diaz; W Rhead; U Lichter-Konecki; J Bartley; A Feigenbaum; N Longo; W Berquist; S A Berry; R Gallagher; D Bartholomew; C O Harding; M S Korson; S E McCandless; W Smith; J Vockley; S Bart; D Kronn; R Zori; S Cederbaum; N Dorrani; J L Merritt; Sandesh Sreenath-Nagamani; M Summar; C Lemons; K Dickinson; D F Coakley; T L Moors; B Lee; B F Scharschmidt Journal: Mol Genet Metab Date: 2012-08-18 Impact factor: 4.797